Navigation Links
Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
Date:5/30/2008

NEW HAVEN, Conn., May 30 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that data from two clinical trials of its lead anticancer agent Cloretazine(R) (VNP40101M) in acute myelogenous leukemia (AML) would be presented in posters at the 2008 American Society of Clinical Oncology (ASCO(R)) Annual Meeting in Chicago, Illinois.

The poster (Abstract #7051) entitled "A double blind placebo-controlled randomized phase III study of high-dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients with first relapse of AML" will be presented at McCormick Place, South Hall A1, Board 38E from 8:00 a.m. to 12:00 p.m. on Saturday, May 31, 2008. A copy of the poster will be available on Vion Pharmaceuticals' website, http://www.vionpharm.com, on May 31, 2008 at 7:00 a.m. Eastern Time.

The poster (Abstract #7025) entitled "A phase II study of VNP40101M in elderly patients with de novo poor risk AML" will be presented at McCormick Place, Room E450a, Board 15 from 2:00 p.m. to 6:00 p.m. on Monday June 2, 2008. A poster discussion will take place at 5:30 p.m. in Room E354a. A copy of the poster will be available on Vion Pharmaceuticals' website, http://www.vionpharm.com, on June 2, 2008 at 1:00 p.m. Eastern Time.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a si
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
2. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
3. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
6. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
7. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...HESTER, Minn., Nov. 26 ...rd are at significantly increased risk of developi... findings of a Mayo Clinic study published this m...merican Academy of Pediatrics. , , The retr...7 patients with strabismus (misaligned eyes) and c...
(Date:11/26/2008)...dy Expanded to 406 Subjects , , FRANKLIN, M...s Inc. (OTC Bulletin Board: PLCSF) announced today...Food and Drug Administration (FDA) for its U.S. pi...any,s RenalGuard System(TM) and associated therap...y (CIN). , , The FDA also approved PLC,s re...
(Date:11/25/2008)...ISVILLE, Ky., Nov. 25 K...urgeons performed the fifth U.S. hand transplant o... at Louisville,s Jewish Hospital Hand Care Center ...began around noon and was completed shortly after ... http://www.newscom.com/cgi-bin/prnh/20081125/DC4...
(Date:11/25/2008)...TH SAN FRANCISCO, Calif., Nov. 25 ...velopment of novel therapeutics that target,prote...iseases, today,announced that data from two ongoi...iple myeloma will be presented at the upcoming 50t...ology (ASH). Carfilzomib is the first in a new cl...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Leading Worldwide Cause of Cardiovascular Disease May Be Modified by Diet 23346 1Leading Worldwide Cause of Cardiovascular Disease May Be Modified by Diet 23346 2Leading Worldwide Cause of Cardiovascular Disease May Be Modified by Diet 23346 3Rocker Joel Madden Named Newest UNICEF Goodwill Ambassador 23343 1Rocker Joel Madden Named Newest UNICEF Goodwill Ambassador 23343 2Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference 23340 1Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference 23340 2Physicians Practice Promotes Key Executives 23337 1Physicians Practice Promotes Key Executives 23337 2
...t Randomized, Placebo-controlled Trial,Ever Conduc...linical Oncology, CHICAGO, June 04, 2007 /PRNewswi...ed, placebo-controlled clinical trial ever,conduct...L) showed,that ONTAK was more than twice as effect... patients with CTCL. [Abstract number 8026],The pr...
...With Follicular Lymphoma Reported,Today at ASCO An...ire/ -- GlaxoSmithKline plc,announced today long-t...e one-week course of frontline treatment with the ...ine I-131 Tositumomab) in,76 patients with newly d...a (NHL). This regimen was found to induce durable ...
Other Medicine Technology:Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 2Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 3Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 4Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 5Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
(Date:12/2/2008)...n Service, one of the premier leaders in medical t...ictation transcription, has joined up with TMATT,...zation geared to the betterment of women and child... Lower Westchester County, New York. , ... -- World Wide Dictation Services of New York, ht...
(Date:12/2/2008)...-- The Healthcare group at,Frost & Sullivan (...nnounce that,it will be hosting a free webinar on...rica on Friday 12 December at 16h00 CAT/14h00 GMT....rnh/20081117/FSLOGO ) , Medical insurance a...elatively novel concept in most sub-Saharan Africa...
(Date:12/2/2008)...leading provider of onsite health services and tec... the athletic products company, has selected Marat... health clinics and to provide health services to ... Burlington, VT (PRWEB) Decembe...f onsite employee health services and technology s...
(Date:12/2/2008)...the problem with the holidays is family. Elder ca...regivers of aging parents can bring the joy of the... San Mateo, CA (PRWEB) Decem... holiday season is family, especially aging parent...ch , founder of Encore Management , has a simple ...
Breaking Medicine News(10 mins):Health News:World Wide Dictation Service Teams up with TMATT for Local Thanksgiving Community Dinner 2Health News:The Future of Financing Health Services in Africa 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3
...n, Deborah Busemeyer, says a man in critical condi...e disease in which the plague bacteria multiply in...County died last week from septicemic form of the ...te from an infected flies or direct contact with i...
...cal College and Hospital has described the critici...ns as baseless. // The superintendent and princip... allegation had no basis. Yesterday around 200 HIV... banner of 'Sanghabaddha' a voluntary organisation...
... reports, ‘Indonesia hasn’t shared the genetic inf...director-general of disease control and environmen...Health, reports that certain things are to be cons...efore any public release and there is more chance ...
...te of British Red Cross (Indonesia), Mark Snelling...ore areas of southern regions of Java island//. O...injured and everyone involved in the relief operat...rs here is an eternity – said latest official repo...
Other Medicine News:
Eyeglass Loupe 3x-5x made with precision optical glass. Ideal for any detail work.
Near PT test card/child recog/ playing cards 5 1/2" X 8".
Near point card/newspaper 8 to 48 point type 5 1/2" X 8".
Near point card 4 1/2 to 24 PT 5 1/2" x 8".
Medicine Products: